Clinical Trials on Siewert Type III Adenocarcinoma of Esophagogastric Junction

Total 2397 results

St. James's Hospital, Ireland

Unknown

Classification of Adenocarcinoma of the Esophagogastric Junction

Barrett Esophagus | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Oesophagus Cancer | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric Junction

Ireland
P. Herzen Moscow Oncology Research Institute
National Medical Research Radiological Centre of the Ministry of Health of...

Not yet recruiting

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery (ESOSTAT)

Esophageal Cancer | Oesophageal Cancer | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric Junction

Russian Federation
Sakti Chakrabarti

Recruiting

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Siewert Type II Adenocarcinoma of Esophagogastric Junction | Adenocarcinoma Esophagus | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Locally Advanced Adenocarcinoma

United States
West China Hospital

Recruiting

Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors

Recurrence | Stomach Neoplasms | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric Junction

China
AIO-Studien-gGmbH
Neovii Biotech

Completed

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (CatuNeo)

Gastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Siewert Type II Adenocarcinoma of Esophagogastric Junction

China
Guangdong Provincial Hospital of Traditional Chinese...

Recruiting

A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG

Siewert Type II Adenocarcinoma of Esophagogastric Junction | Esophagogastric Junction Adenocarcinoma

China
University of Bologna

Completed

Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival (SiewertIIEAC)

Siewert Type II Adenocarcinoma of Esophagogastric Junction

Italy
Xijing Hospital of Digestive Diseases
First Affiliated Hospital Xi'an Jiaotong University; Henan Provincial People... and other collaborators

Recruiting

Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

Siewert Type II Adenocarcinoma of Esophagogastric Junction

China
Northern Jiangsu People's Hospital

Completed

A 3-Arm Study Comparing the Efficacy of Anti-Reflux Reconstruction Protocols After Laparoscopic Proximal Gastrectomy

Anti-Reflux Alimentary Reconstruction | Laparoscopic Proximal Gastrectomy | Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction

China
P. Herzen Moscow Oncology Research Institute
National Medical Research Radiological Centre of the Ministry of Health of...

Not yet recruiting

Postoperative Morbidity and Mortality After Gastric Cancer Surgery (GASTROSTAT)

Stomach Cancer | Gastric Cancer | Siewert Type III Adenocarcinoma of Esophagogastric Junction

Russian Federation
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8 | Pathologic... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Withdrawn

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditions

United States
National Center for Tumor Diseases, Heidelberg

Terminated

Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) (HICON)

Adenocarcinomas of the Esophagogastric Junction

Germany
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma (Siewert II-III)

China
Peking University People's Hospital

Not yet recruiting

Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma (NICLA)

Adenocarcinoma of Esophagogastric Junction

China
Technical University of Munich

Completed

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (MEMORI)

Adenocarcinoma of the Esophagogastric Junction

Germany
Fujian Medical University Union Hospital

Completed

Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Adenocarcinoma of the Esophagogastric Junction

China
Yu jiren

Recruiting

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Proficient Mismatch Repair

China
Peking University

Recruiting

A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy

Proximal Gastric Adenocarcinoma | Anastomosis | Adenocarcinoma of Esophagogastric Junction

China
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Mismatch Repair Deficiency | Adenocarcinoma of Esophagogastric Junction

China
Genta Incorporated

Unknown

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction

United States, Korea, Republic of
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Fudan University

Unknown

Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction (GCQOL01)

Adenocarcinoma of Esophagogastric Junction.

China
Fujian Cancer Hospital

Unknown

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Gastric Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Esophagogastric Junction Adenocarcinoma

China
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric Cancer | Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction

China
Fujian Cancer Hospital

Unknown

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
University Hospital Schleswig-Holstein
University of Leipzig; University of Luebeck; University of Hamburg-Eppendorf; University... and other collaborators

Active, not recruiting

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (ESOPEC)

Adenocarcinoma of the Esophagogastric Junction | Esophageal Adenocarcinoma (UICC TNM7)

Germany
Ruijin Hospital

Recruiting

Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study (AEGIS)

Esophagogastric Junction Adenocarcinoma

China
Fujian Medical University

Enrolling by invitation

Clinical Outcomes of Robotic Versus Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III AEG

Esophagogastric Junction Adenocarcinoma

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIB Gastroesophageal... and other conditions

United States
Krankenhaus Nordwest

Completed

Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT3)

Gastric Cancer | Adenocarcinoma of the Esophagogastric Junction

Germany
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (S-1 adjuvant)

Adenocarcinoma,Stomach | Adenocarcinoma, Esophagogastric Junction

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditions

United States
Henan Cancer Hospital

Recruiting

PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma

Gastric and Esophagogastric Junction Adenocarcinoma

China
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Roswell Park Cancer Institute
Pfizer

Recruiting

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Advanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Centre Hospitalier Universitaire Dijon

Terminated

Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy (Esostrate)

Epidermoid Carcinoma or | Adenocarcinoma of the Thoracic Oesophagus or | Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) | Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditions

United States
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma

Neoplasms | Esophagogastric Junction Disorder
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery

Adenocarcinoma of the Gastroesophageal Junction | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma

United States
Ruihua Xu

Recruiting

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

China
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
Biotech Pharmaceutical Co., Ltd.

Recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma

China

Clinical Trials on Siewert Type III Adenocarcinoma of Esophagogastric Junction

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations